World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
129
Citations
74493
World Ranking
2555
National Ranking
1436

Charles S. Cleeland publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Charles S. Cleeland sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 694 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Charles S. Cleeland D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Charles S. Cleeland sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 129 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 1982 - Fellow of the American Psychological Association (APA)

Overview

Charles S. Cleeland is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine with a substantial concentration in Oncology, Surgery, Pulmonary and Respiratory Medicine, Economics and Econometrics, and Public Health, Environmental and Occupational Health.

The main topics addressed in their work include:

  • Cancer survivorship and care
  • Health Systems, Economic Evaluations, Quality of Life
  • Cancer Treatment and Pharmacology
  • Economic and Financial Impacts of Cancer
  • Palliative Care and End-of-Life Issues
  • Childhood Cancer Survivors' Quality of Life
  • Multiple Myeloma Research and Treatments

Charles S. Cleeland has contributed to various peer-reviewed journals, with frequent publications in:

  • Journal of Clinical Oncology
  • UNC Libraries
  • Annals of Surgical Oncology
  • JCO Oncology Practice
  • Journal of Patient-Reported Outcomes

The following recent papers illustrate the scope of their work and collaborations within oncology and patient-reported outcome research:

  • International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium, 2020, The Lancet Oncology
  • Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), 2020, Clinical Trials
  • Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group, 2023, The Lancet Oncology
  • Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma, 2020, Supportive Care in Cancer
  • Symptom Trajectories Informing Patient Care After Lung Cancer Surgery: A Longitudinal Patient-Reported Outcome Study, 2023, Annals of Surgical Oncology

Their frequent co-authors include:

  • Xin Shelley Wang
  • Tito R. Mendoza
  • Qiuling Shi
  • Loretta A. Williams
  • Mona Kamal

Charles S. Cleeland was recognized as a Fellow of the American Psychological Association (APA) in 1982.

Best Publications

  • Pain assessment: Global use of the Brief Pain Inventory.

    Cleeland Cs;Ryan Km

  • Core outcome domains for chronic pain clinical trials: IMMPACT recommendations.

    Dennis C Turk;Robert H Dworkin;Robert R Allen;Nicholas Bellamy

  • Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations

    Robert H. Dworkin;Dennis C. Turk;Kathleen W. Wyrwich;Dorcas Beaton

  • Pain and its treatment in outpatients with metastatic cancer.

    Charles S. Cleeland;Rene Gonin;Alan K. Hatfield;John H. Edmonson

  • The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory.

    Tito R. Mendoza;X. Shelley Wang;Charles S. Cleeland;Marilyn Morrissey

  • Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases

    Randall L. Daut;Charles S. Cleeland;Randall C. Flanery

  • When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.

    Ronald C. Serlin;Tito R. Mendoza;Yoshio Nakamura;Katherine R. Edwards

  • Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory

    Charles S. Cleeland;Tito R. Mendoza;Xin Shelley Wang;Chyi Chou

  • Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain.

    San Keller;Carla M. Bann;Sheri L. Dodd;Jeff Schein

  • Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Ethan Basch;Ethan Basch;Bryce B. Reeve;Sandra A. Mitchell;Steven B. Clauser

  • Physician attitudes and practice in cancer pain management: A survey from the Eastern Cooperative Oncology Group

    J. H. Von Roenn;C. S. Cleeland;R. Gonin;A. K. Hatfield

  • Cancer-Related Fatigue, Version 2.2015

    Ann Malone Berger;Kathi Mooney;Amy Alvarez-Perez;William S. Breitbart

  • Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.

    William F. Harstell;Charles B. Scott;Deborah Watkins Bruner;Charles W. Scarantino

  • Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Amylou C. Dueck;Tito R. Mendoza;Sandra A. Mitchell;Bryce B. Reeve

  • Quality Improvement Guidelines for the Treatment of Acute Pain and Cancer Pain

    Mitchell B. Max;Marilee Donovan;Christine A. Miaskowski;Sandra E. Ward

  • The prevalence and severity of pain in cancer.

    Randall L. Daut;Charles S. Cleeland

  • Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing

    Janice L. Gabrilove;Charles S. Cleeland;Robert B. Livingston;Brenda Sarokhan

  • Pain and Treatment of Pain in Minority Patients with Cancer: The Eastern Cooperative Oncology Group Minority Outpatient Pain Study

    Charles S. Cleeland;René Gonin;Luis Baez;Patrick Loehrer

  • Assessing symptom distress in cancer patients. The M.D. Anderson symptom inventory. (The University of Texas M. D. Anderson Cancer Center, Houston, Texas) Cancer 2000;89:1634–1646.

    Charles S. Cleeland;Tito R. Mendoza;Xin Shelley Wang;Chyi Chou

  • When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.

    R E Serlin;Rodrigo Y. M. Nakamura;Tito R Mendoza;Andrew K. Edwards

Frequent Co-Authors

Tito R. Mendoza
Tito R. Mendoza The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
David I. Rosenthal
David I. Rosenthal The University of Texas MD Anderson Cancer Center
Ethan Basch
Ethan Basch University of North Carolina at Chapel Hill
Jeff A. Sloan
Jeff A. Sloan Mayo Clinic
Bryce B. Reeve
Bryce B. Reeve Duke University
James M. Reuben
James M. Reuben The University of Texas MD Anderson Cancer Center
Adam S. Garden
Adam S. Garden The University of Texas MD Anderson Cancer Center
Valen E. Johnson
Valen E. Johnson Texas A&M University
Lesley Fallowfield
Lesley Fallowfield University of Sussex

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative medical career pathways or advancing your credentials online is increasingly popular among those considering or already pursuing Medicine in the USA. If you’re interested in nursing, there are a variety of accessible and flexible online degree options to help you reach your goals.

For those seeking advanced expertise, cheapest phd nursing programs offer affordable routes for earning a terminal degree in nursing practice or research. Similarly, registered nurses can find degree completion programs such as the what is the cheapest rn to bsn program online, providing cost-effective ways to advance their credentials and qualify for more competitive job roles.

If you hold a non-nursing bachelor’s and want to switch to nursing, consider direct entry msn programs online. These accelerated programs are designed for career changers and offer a streamlined path to a master’s in nursing. Additionally, if you're searching for a flexible admission process, learn more about nursing schools with high acceptance rates, making it easier to start your journey in healthcare.

Best Scientists Citing Charles S. Cleeland

Trending Scientists

Recently Published Articles